Welcome to our dedicated page for Yield10 Bioscience news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on Yield10 Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Yield10 Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Yield10 Bioscience's position in the market.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced a public offering of 835,000 shares at $4.25 per share, aiming to raise approximately $3.5 million before expenses. Concurrently, existing investors of Jack W. Schuler will purchase 396,450 shares in a private placement, raising an additional $1.7 million. Both offerings are expected to close around August 26, 2020. Maxim Group LLC is the sole book-running manager, with a 45-day option for the underwriter to acquire 125,250 more shares. The shares in the private placement are not registered under the Securities Act of 1933.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced an underwritten public offering of its common stock, alongside a private placement with investors affiliated with Jack W. Schuler. The private placement will occur concurrently with the public offering, with share prices matching those in the public offering. Both transactions are subject to market conditions and are contingent upon the public offering's closure. Maxim Group LLC serves as the sole book-running manager. The offerings follow a shelf registration statement filed with the SEC.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced a positive response from USDA-APHIS regarding its CRISPR genome-edited trait C3007 in canola, designed to increase oil content. This regulatory confirmation allows Yield10 to conduct field tests in the U.S. during the 2021 growing season. C3007 could significantly enhance oil biosynthesis, representing a potential economic opportunity in specialty oilseed crops. Yield10 continues to develop other traits aimed at boosting seed yield, positioning itself as a leader in agricultural bioscience.
Yield10 Bioscience (Nasdaq: YTEN) announced a three-year non-exclusive research agreement with GDM, focusing on evaluating novel soybean yield traits. GDM will incorporate Yield10's traits into its R&D efforts to enhance soybean yield performance and sustainability. The partnership aims to explore further collaboration leveraging Yield10’s GRAIN platform and GDM’s rapid trait editing capabilities. Preliminary greenhouse and field tests have shown promising results, such as improved vigor and seed yield, indicating potential for significant yield benefits in soybeans.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) will announce its second quarter 2020 financial results and corporate update on August 11, 2020. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results and answer questions from participants. Investors can access the call by dialing specified numbers or via a live webcast. Yield10 specializes in agricultural bioscience, focusing on crop innovations to improve yields. The company utilizes its proprietary GRAIN platform for gene discovery aimed at enhancing food security.
Yield10 Bioscience (Nasdaq: YTEN) announced that it successfully established 50 acres of spring Camelina in Montana during Q2 2020. This initiative aims to enhance the company’s value chain for large-scale Camelina sativa seed production. The crop is currently drying, with harvest expected soon. CEO Oliver Peoples described this achievement as a significant milestone, supporting the company's strategy for Camelina seed products. Yield10 focuses on developing improved varieties and fostering partnerships to commercialize Camelina oil and meal.
Yield10 Bioscience (Nasdaq: YTEN) has obtained all necessary regulatory permits for field testing multiple traits in Camelina and canola across the U.S. and Canada for the 2020 growing season. This marks the company's largest field test program, aiming to evaluate novel traits for enhanced crop yields and oil content. Key traits include C3004, CRISPR E3902, and others focused on improving seed yield and producing PHA biomaterials. Planting is anticipated in Q2 2020, contingent on weather conditions.
Yield10 Bioscience, Inc. (NASDAQ: YTEN) announced it will report its first quarter 2020 financial results and provide a corporate update on May 14, 2020. Management will host a conference call at 6:00 p.m. ET to review the results and highlight corporate developments, followed by a Q&A session. The call will be accessible via phone and a live webcast. Yield10 develops agricultural innovations to enhance crop yields and food security, using its proprietary GRAIN platform. The replay of the call will be available until May 28, 2020.